Published: Jan. 5, 2024 at 4:12 p.m. ET
By Will Feuer
PMV Pharmaceuticals Chief Financial Officer Winston Kung has stepped down and will be succeeded by Michael Carulli.
Kung has served as CFO of the precision-oncology company since 2017. He is stepping down to pursue other opportunities, the company said. Carulli joined the company in 2020, ahead of the company’s initial public…
By Will Feuer
PMV Pharmaceuticals Chief Financial Officer Winston Kung has stepped down and will be succeeded by Michael Carulli.
Kung has served as CFO of the precision-oncology company since 2017. He is stepping down to pursue other opportunities, the company said. Carulli joined the company in 2020, ahead of the company’s initial public offering.
PMV shuffled other leadership. The company’s PC14586 clinical program will now be led by Deepika Jalota and Marc Fellous, succeeding Leila Alland, who is stepping down to pursue other opportunities.
Tim Smith, senior vice president and head of corporate development will also extend his responsibilities to include Investor Relations.
General Counsel Robert Ticktin will expand his responsibilities to include management of human resources, IT and facilities.
Write to Will Feuer at Will.Feuer@wsj.com
